ADCY10 and prostate carcinoma: Such important disadvantage has stimulated the search of more specific inhibitors of Mps1 kinase activity, such as the compound CFI-402257, which prevents activation of the SAC, impacting cancer cells survival by preventing cells progression to anaphase and inducing cell death in breast, colorectal, pancreatic, lung, and prostate cancer cell lines (Table 1) [63].